These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 37155984

  • 21. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
    Lee HF, Chan YH, Chuang C, Li PR, Yeh YH, Hsiao FC, Peng JR, See LC.
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun 02; 9(4):301-310. PubMed ID: 36639127
    [Abstract] [Full Text] [Related]

  • 22. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.
    Barkmeier AJ, Herrin J, Swarna KS, Deng Y, Polley EC, Umpierrez GE, Galindo RJ, Ross JS, Mickelson MM, McCoy RG.
    Ophthalmol Retina; 2024 Oct 02; 8(10):943-952. PubMed ID: 38735641
    [Abstract] [Full Text] [Related]

  • 23. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y, Boyle TA, Lyu B, Ballew SH, Selvin E, Chang AR, Inker LA, Grams ME, Shin JI.
    J Gen Intern Med; 2024 May 02; 39(7):1112-1121. PubMed ID: 38191976
    [Abstract] [Full Text] [Related]

  • 24. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
    Paik JM, Tesfaye H, Curhan GC, Zakoul H, Wexler DJ, Patorno E.
    JAMA Intern Med; 2024 Mar 01; 184(3):265-274. PubMed ID: 38285598
    [Abstract] [Full Text] [Related]

  • 25. The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors.
    Huang W, Whitelaw J, Kishore K, Neto AS, Holmes NE, Marhoon N, Bellomo R, Ekinci EI.
    J Diabetes Complications; 2023 Aug 01; 37(8):108522. PubMed ID: 37311358
    [Abstract] [Full Text] [Related]

  • 26. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM, Tan KCB, Lam DCL, Cheung BMY, Wong ICK, Kwok WC, Sing CW, Cheung CL.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2251177. PubMed ID: 36648944
    [Abstract] [Full Text] [Related]

  • 27. Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study.
    Lin DS, Lo HY, Huang KC, Lin TT, Lee JK, Lin LY.
    Diabetes Obes Metab; 2024 Oct 03; 26(10):4386-4396. PubMed ID: 39030922
    [Abstract] [Full Text] [Related]

  • 28. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, Yeh YH, Kuo CT, Chan YH, See LC.
    Cardiovasc Diabetol; 2020 Sep 30; 19(1):160. PubMed ID: 32998736
    [Abstract] [Full Text] [Related]

  • 29. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
    Mui JV, Li L, Chou OHI, Azfar N, Lee A, Hui J, Lee S, Tse G, Zhou J.
    Acta Diabetol; 2023 Jul 30; 60(7):917-927. PubMed ID: 37000300
    [Abstract] [Full Text] [Related]

  • 30. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors.
    Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chen WJ.
    Diabetologia; 2022 Dec 30; 65(12):2032-2043. PubMed ID: 35945333
    [Abstract] [Full Text] [Related]

  • 31. Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.
    Lin YH, Lin CH, Lin YC, Huang YY, Tai AS, Fu SC, Lin SH.
    Endocr Pract; 2024 May 30; 30(5):424-430. PubMed ID: 38325629
    [Abstract] [Full Text] [Related]

  • 32. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e012940. PubMed ID: 31902326
    [Abstract] [Full Text] [Related]

  • 33. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors.
    Lin DS, Lee JK, Chen WJ.
    Diabetologia; 2021 Sep 07; 64(9):1949-1962. PubMed ID: 34195865
    [Abstract] [Full Text] [Related]

  • 34. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study.
    Prázný M, Suplotova L, Gumprecht J, Kamenov Z, Fülöp T, Medvedchikov A, Rosenzweig D, Aleksandric M.
    Cardiovasc Diabetol; 2022 Oct 08; 21(1):203. PubMed ID: 36209118
    [Abstract] [Full Text] [Related]

  • 35. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Oct 08; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 36. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, Chu PH.
    Cardiovasc Diabetol; 2020 Nov 06; 19(1):188. PubMed ID: 33158436
    [Abstract] [Full Text] [Related]

  • 37. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs.
    Alkabbani W, Gamble JM, Eurich DT, Minhas-Sandhu JK, Shah BR, Alsabbagh MW, Zongo A.
    Diabetes Metab; 2022 Mar 06; 48(2):101305. PubMed ID: 34808344
    [Abstract] [Full Text] [Related]

  • 38. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
    Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Yan Y, Al-Aly Z.
    Diabetes Care; 2020 Nov 06; 43(11):2859-2869. PubMed ID: 32938746
    [Abstract] [Full Text] [Related]

  • 39. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.
    Chen Y, Lv X, Lin S, Arshad M, Dai M.
    Front Endocrinol (Lausanne); 2022 Nov 06; 13():895458. PubMed ID: 35692410
    [Abstract] [Full Text] [Related]

  • 40. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
    Gamble JM, Thomas JM, Twells LK, Midodzi WK, Majumdar SR.
    Medicine (Baltimore); 2016 Jun 06; 95(26):e3995. PubMed ID: 27368005
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.